A microenvironment based model of antimitotic therapy of gompertzian tumor growth

Bulletin of Mathematical Biology

Volumn 69, Issue 5, 2007, Pages 1691-1708

  Kozusko, Frank ^a   Bourdeau, Michele ^b   Bajzer, Zeljko ^c   Dingli, David ^c,d  

^a HAMPTON UNIVERSITY   (United States)

^b LEHMAN BROTHERS   (United States)

^c MAYO CLINIC   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Cell kinetics; Chemotherapy; Gompertz; Proliferation; Tumor

Indexed keywords

ANTIMITOTIC AGENT;

ALGORITHM; ARTICLE; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; DRUG EFFECT; HUMAN; KINETICS; NEOPLASM; PARATHYROID TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ALGORITHMS; ANTIMITOTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; HUMANS; KINETICS; MODELS, BIOLOGICAL; NEOPLASMS; PARATHYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 34250785124     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-006-9186-5     Document Type: Article

References (27)

1. Bertuzzi, A., D'Onofrio, A., Fasano, A., Gandolfi, A., 2003. Regression and regrowth of tumour cords following single-dose anticancer treatment. Bull. Math. Biol. 65, 903-931.
2. Bonadonna, G., Zambetti, M., Moliterni, A., Gianni, L., Valagussa, P., 2004. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J. Clin. Oncol. 22, 1614-1620.
3. Bonadonna, G., Zambetti, M., Valagussa, P., 1995. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273, 542-547.
4. Byrne, H.T., 2003. Modeling avascular tumor growth. Cancer modeling and simulation. In: L. Preziosi (Ed.), Chapman & Hall/CRC, New York, pp. 80-86.
5. Citron, M.L., Berry, D.A., Cirrincione, C., Hudis, C., Winer, E.P., Gradishar, W.J., Davidson, N.E., Martino, S., Livingston, R., Ingle, J.N. et al., 2003. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439.
6. Cojocaru, L., Agur, Z., 1992. A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Math. Biosci. 109, 85-97.
7. de Vladar, H.P., Gonzalez, J.A., 2004. Dynamic response of cancer under the influence of immunological activity and therapy. J. Theor. Biol. 227, 335-348.
8. Dyson, J., Villella-Bressan, R., Webb, G.F., 2002. Asynchronous exponential growth in an age structured population of proliferating and quiescent cells. Math. Biosci. 177/178, 73-83.
9. Jackson, T.L., Byrne, H.M., 2000. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math. Biosci. 164, 17-38.
10. Kozusko, F., Bajzer, Z., 2003. Combining Gompertzian growth and cell population dynamics. Math. Biosci. 185, 153-167.
11. Kozusko, F., Chen, P., Grant, S.G., Day, B.W., Panetta, J.C., 2001. A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math. Biosci. 170, 1-16.
12. Magni, P., Simeoni, M., Poggesi, I., Rocchetti, M., De Nicolao, G., 2006. A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math. Biosci. 200, 127-151.
13. Norton, L., 2005. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 10, 370-381.
14. Norton, L., Simon, R., 1977. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 61, 1307-1317.
15. Norton, L., Simon, R., 1986. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70, 163-169.
16. Norton, L., Simon, R., Brereton, H.D., Bogden, A.E., 1976. Predicting the course of Gompertzian growth. Nature 264, 542-545.
17. Panetta, J.C., 1996. A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment. Bull. Math. Biol. 58, 425-447.
18. Panetta, J.C., 1997. A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci. 146, 89-113.
19. Panetta, J.C., Kirstein, M.N., Gajjar, A.J., Nair, G., Fouladi, M., Stewart, C.F., 2003. A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math. Biosci. 186, 29-41.
20. Panetta, J.C., Webb, G.F., 1995. A mathematical model of cycle-specific chemotherapy. Math. Comput. Modell. 22, 67.
21. Parfitt, A.M., Fyhrie, D.P., 1997. Gompertzian growth curves in parathyroid tumours: further evidence for the set-point hypothesis. Cell. Prolif. 30, 341-349.
22. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rube, C., Rudolph, C., Reiser, M., Hossfeld, D.K., Eimermacher, H. et al., 2004a. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104, 634-641.
23. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rudolph, C., Reiser, M., Hossfeld, D.K., Metzner, B., Hasenclever, D. et al., 2004b. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104, 626-633.
24. Ribba, B., Marron, K., Agur, Z., Alarcon, T., Maini, P.K., 2005. A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. Bull. Math. Biol. 67, 79-99.
25. Sidorov, I.A., Hirsch, K.S., Harley, C.B., Dimitrov, D.S., 2003. Cancer treatment by telomerase inhibitors: predictions by a kinetic model. Math. Biosci. 181, 209-221.
26. Sullivan, P.W., Salmon, S.E., 1972. Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51, 1697-1708.
27. Wheldon, T.E., 1988. Mathematical models in cancer research. Adam Hilger, Bristol, pp. 157-179.